Analyst Price Targets — BDX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 10, 2026 1:54 pm | Shagun Singh | RBC Capital | $172.00 | $170.14 | TheFly | Becton Dickinson price target lowered to $172 from $210 at RBC Capital |
| February 10, 2026 12:15 pm | Matt Miksic | Barclays | $202.00 | $207.39 | TheFly | Becton Dickinson reinstated with an Overweight at Barclays |
| February 10, 2026 11:28 am | — | Piper Sandler | $170.00 | $207.39 | TheFly | Becton Dickinson price target lowered to $170 from $205 at Piper Sandler |
| January 28, 2026 11:51 am | Jason Bednar | Piper Sandler | $205.00 | $203.40 | TheFly | Becton Dickinson price target raised to $205 from $190 at Piper Sandler |
| January 7, 2026 12:34 pm | — | Stifel Nicolaus | $215.00 | $205.36 | TheFly | Becton Dickinson price target raised to $215 from $210 at Stifel |
| December 17, 2025 12:23 pm | — | RBC Capital | $210.00 | $196.39 | TheFly | Becton Dickinson price target raised to $210 from $202 at RBC Capital |
| December 2, 2025 11:37 am | Patrick Wood | Morgan Stanley | $210.00 | $191.82 | TheFly | Becton Dickinson price target raised to $210 from $197 at Morgan Stanley |
| April 23, 2025 11:35 am | Jason Bednar | Piper Sandler | $260.00 | $202.32 | TheFly | Becton Dickinson price target lowered to $260 from $280 at Piper Sandler |
| October 1, 2024 8:38 am | Vijay Kumar | Evercore ISI | $290.00 | $241.10 | TheFly | Becton Dickinson target raised, added to 'Tactical Outperform' list at Evercore |
| October 1, 2024 5:29 am | Joanna Wuensch | Citigroup | $275.00 | $241.93 | StreetInsider | Citi Upgrades Becton Dickinson (BDX) to Buy |
Latest News for BDX
The first and only innovation of its kind to receive 510(k) clearance, Surgiphor™ 1000mL empowers surgical teams with a consistent, antimicrobial solution designed to improve patient care and operating room (OR) efficiency FRANKLIN LAKES, N.J., March 2, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it received 510(k) clearance from…
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) is up 9.39% YTD in 2026, decisively outperforming SPY's 1.08%. Dividend Aristocrats are regaining momentum after a weak 2025, with 55 outpacing SPY and 39 posting double-digit gains this year already. Dividend growth is lagging, with 2026's average increase currently at 3.22%, below last year's trend and potentially signaling headwinds.
FRANKLIN LAKES, N.J., Feb. 25, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) (the "Company" or "BD"), a leading global medical technology company, today announced the consideration payable in connection with its previously announced Tender Offers (as defined below) to purchase for cash up to $2,000,000,000 aggregate purchase price, excluding the applicable Accrued Interest (as defined below)…
FRANKLIN LAKES, N.J., Feb. 25, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) (the "Company" or "BD"), a leading global medical technology company, today announced the early tender results for its previously announced Tender Offers (as defined below) to purchase for cash certain of its outstanding debt securities listed in the table below.
BDX launches a three-tube urine collection kit to expand testing from one sample, aiming to boost lab efficiency and reduce contamination risks.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.